Posts by ASPC
Bayer’s KERENDIA® (finerenone) Receives Updated Label to Include Findings From Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes
Read more…
Read MoreACC Recognizes PA Title Change to Physician Associate
We are thrilled to share the official writeup for Physician Associates in ACC’s Cardiology Magazine, with comment from our APAC President Viet Le, PA-C FACC FAHA. Following endorsement by the ACC’s Cardiovascular Team Section PA Work Group and Membership Committee, the ACC Board of Trustees recently approved use of the “Physician Associate” designation in future…
Read MoreThe First Coffee & Coaching Session by Women in Preventive Cardiology (WIPC) Working Group: Disney Creative Thinking Strategy
by Panteha Rezaeian, MD; Suvasini Lakshmanan, MD; and Sherry-Ann Brown, MD, PhD The Women in Preventive Cardiology (WIPC) working group had our first formal meeting in January 2021 with the purpose “to support and mentor women in preventive cardiology and to advocate for women’s cardiovascular health by promoting optimal treatment and transdisciplinary research to improve…
Read MoreASPC Announces Official Program Covering the ABCs of Preventive Cardiology at Premier Annual Congress on CVD Prevention
JACKSONVILLE, Fla. – The American Society for Preventive Cardiology (ASPC) announces the official program for the ASPC 2022 Congress on CVD Prevention, scheduled July 29-31, 2022 in Louisville, KY. The program covers the “ABCs of Preventive Cardiology” over the 2.5 day live, in-person program, and can be found on aspconline.org/2022congress. Included in the 2022 program…
Read MoreJardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
OXFORD, United Kingdom and RIDGEFIELD, Conn. and INDIANAPOLIS, March 16, 2022 /PRNewswire/ — The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee. This follows a formal interim assessment that met prespecified criteria for positive efficacy, announced the Medical Research Council (MRC) Population…
Read MoreREGENERON AND ULTRAGENYX COLLABORATE TO COMMERCIALIZE EVKEEZA® (EVINACUMAB) OUTSIDE THE UNITED STATES
Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultra-rare inherited form of high cholesterol TARRYTOWN, N.Y. and NOVATO, Calif., Jan. 7, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and distribute Evkeeza® (evinacumab)…
Read MoreFDA Approval of LEQVIO(R) (inclisiran)
Novartis has announced that LEQVIO® (inclisiran) has been approved by the FDA for patients with atherosclerotic cardiovascular disease (ASCVD) who need to further lower their bad cholesterol, despite being on a maximally tolerated statin. If interested, the LEQVIO full prescribing information can be found here: https://www.novartis.us/sites/www.novartis.us/files/leqvio.pdf Novartis is committed to continuing their work with the…
Read More2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Read More
Read MoreHow to Integrate Preventive Cardiovascular Medicine into Cardiology Fellowship Training
by Mahmoud Al Rifai, MD, Yousif Al-Saiegh, MD and Anurag Mehta, MD Cardiovascular disease (CVD) remains the most common cause of morbidity and mortality in the United States.1 However, significant improvement has been made in management of CVD over the past three decades in the United Status which is attributable to population shift in risk…
Read MoreFinding a Job as a Preventive Cardiologist
by Charles German, MD, MS and Nicole Harkin, MD Increasing rates of sedentary behavior and low levels of physical activity, coupled with the rise in cardiometabolic diseases, have highlighted a critical need for atherosclerotic cardiovascular disease prevention, and preventive cardiologists are at the forefront of this public health crisis. However, few trainees receive adequate exposure…
Read More